RE: cannacordSS, the sts phase 111's actually couldn't be in a better position. The company is limited as to what they say .The Childrens Oncology Group is going to not only run the trials (as per the WSJ) BUT THEY ARE GOING TO PAY FOR THEM. It doesn't get any better than that, thus the companies position of not being able to say to much until they are announced and under way.
A theory has been put to me that we are not seeing much buy side support buy the big boys is simply due to a liquidity factor and they are waiting to step up once on the Amex, and don't wish to accumulate anymore in the Canadian Emerging Market - TSX.
Note phase11's can start without the completion of the phase1's as they have already hit the green light qualifications to move to the next trials - efficacy of some nature below the MTD levels.
My guess on the phase1's finishing up 3-6 months- of which I have no problems with.
PPS -summer duldrums now, more importantly- a saturated Canadian market and an unsophisticated Canadian investor-the doors that AHX's Advisory board can open is absolutely unparalled and going forward this will become even more apparent.Look at the influence that they already have had (including Peters)
NCI to take all their compounds through phase3's
Childrens Oncology Group to do the phase3 STS trials and pay for them
Exherin trials to be held at M.D.ANDERSON
Not to mention the Tier one people they continue to attract like Dr.Chabner world renoun clinical trial designer.
HBM - Vengrowth - Orbimed all getting a piece of the action in the companies infancy.
All in all doing the right things - ahead on the milestones .
Note don't read to much into Prakash Gowds call ' after recent discussions with management'as he DID NOT SPEAK TO ANYONE AT THE COMPANY. Ask Peters for yourself.
See you all in the fall we this becomes a real going concern.
Comms